The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Momenta Pharmaceuticals Inc

Nasdaq: MNTA
Last

(U.S.) $9.19

Today's change-0.57 -5.84%
Updated May 3 4:00 PM EDT. Delayed by at least 15 minutes.
 

Momenta Pharmaceuticals Inc

Nasdaq: MNTA
Last

(U.S.) $9.19

Today's change-0.57 -5.84%
Updated May 3 4:00 PM EDT. Delayed by at least 15 minutes.

Momenta Pharmaceuticals Inc crosses below 20-day moving average

Momenta Pharmaceuticals Inc closed sharply lower Tuesday, dropping (U.S.)$0.57 or 5.84% to (U.S.)$9.19 and crossing below its 20-day moving average. Over the last five days, shares have lost 1.29% and are down 38.07% for the last year to date. This security has underperformed the S&P 500 by 47.32% during the last year.

Key company metrics

  • Open(U.S.) $9.48
  • Previous close(U.S.) $9.76
  • High(U.S.) $9.62
  • Low(U.S.) $8.82
  • Bid / Ask(U.S.) $8.80 / (U.S.) $15.15
  • YTD % change-38.07%
  • Volume1,042,197
  • Average volume (10-day)480,351
  • Average volume (1-month)489,041
  • Average volume (3-month)674,262
  • 52-week range(U.S.) $7.86 to (U.S.) $25.56
  • Beta1.88
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.31
Updated May 3 4:00 PM EDT. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue2214459
Total other revenue--------
Total revenue2214459
Gross profit--------
Total cost of revenue--------
Total operating expense52444731
Selling / general / administrative1412138
Research & development38323423
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-30-30-2-22
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-29-30-2-22
Income after tax-29-30-2-22
Income tax, total--------
Net income-29-30-2-22
Total adjustments to net income--------
Net income before extra. items-29-30-2-22
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-29-30-2-22
Inc. avail. to common incl. extra. items-29-30-2-22
Diluted net income-29-30-2-22
Dilution adjustment--------
Diluted weighted average shares68686254
Diluted EPS excluding extraordinary itemsvalue per share-0.43-0.44-0.04-0.40
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.43-0.44-0.04-0.40